Published 4 days ago • loading... • Updated 3 days ago
Dren Bio Pockets $350m for Rare Blood Cancer Programme
Summary by Pharmaphorum
4 Articles
4 Articles
US biotech company Dren Bio has raised $350 million in a new investment round, securing significant funding to fund key clinical trials of its potentially first-of-its-kind therapy for rare blood malignancies and other diseases.
Dren Bio raises $350m for dibotatug clinical development
Dren Bio has secured $350m in an oversubscribed private financing round to advance its primary investigational therapy, dibotatug, through late-stage clinical evaluation, regulatory submission, and potential commercialisation.
Exclusive: Dren Bio nabs $350M for potential 2027 launch of blood cancer drug
Dren Bio has raised $350 million, hoping to get its lead blood cancer drug onto the market by the end of 2027, the California drug developer exclusively told Endpoints News. The Thursday morning haul will ...
Coverage Details
Total News Sources4
Leaning Left1Leaning Right0Center1Last Updated50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium






